WE NEED ODX12 Nov 2020 09:57
The study by Mulchandani and colleagues identifies notable limitations of the UK government’s antibody test of choice and provides good evidence that its specificity in a “real life” setting is highly unlikely to be 100%. Apart from limited surveillance to estimate the proportion of a population that has been infected,9 widespread use of this assay in any other role could risk considerable harm.